| Prev Close | 82.14 |
| Open | 83.88 |
| Day Low/High | 83.57 / 84.62 |
| 52 Wk Low/High | 69.18 / 99.84 |
| Volume | 1.53M |
| Avg Volume | 1.84M |
Novartis AG (NVS)
83.89
1.80
2.10
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.47B |
| Market Cap | 217.73B |
| EPS | 3.10 |
| P/E Ratio | 26.98 |
| Div & Yield | 2.01 (2.29%) |
Friday Small-Cap Focus: Xoma
Small biotech plunged in July, but has stabilized on two key deals.
Schlumberger, Lowe’s Shares Heading Higher Says Edward Jones Strategist
Underlying support for stock prices remains positive, especially if oil prices stabilize near current levels and the dollar does not rise a lot further.
J&J, Eli Lilly Healthy for Your Portfolio Says Causeway Global Manager
Healthcare stocks were hit hard in the third quarter after leading the S&P 500 for the first half of the year.
Global Stocks Fall After the Federal Reserve Keeps Rates at Record Low
And four other things you need to know now.
When Eyeing Small Biotechs, Partnerships Are Huge
Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.
Quant Picks: 4 Pharmaceutical Companies to Add to Your Porfolio
Here are some of the best pharmaceuticals our algorithm says you should consider looking at.
Quant Picks: 3 Pharmaceutical Companies That Pay High Dividends
Here are some of the best pharmaceutical companies, that pay high dividends, TheStreet Quant Ratings says you should consider looking at.
European Markets Gain as Greece Faces Sunday Debt-Deal Ultimatum
European markets rose Wednesday after European leaders gave Greece a Sunday ultimatum for a final rescue deal or face eviction from the single currency.
What's So Great About an Up Opening?
Don't rely on Europe; it's too out of sync with U.S.
You Have to Love Biotech
In this era of turmoil, investors can take comfort in this sector.
Merger Mania Benefits Mylan
Whether it's acquiring or the acquired, Mylan is building shareholder value.
Rules of the Game: Portfolio Review Time
Let's take a little tour through the various equity asset classes.
Profit From the Longer Life Spans, Part 1
Americans are living much longer these days -- and there are a number of ways to invest.
Riding the Coattails of Mega-Caps
A selection based on James P. O'Shaughnessy's strategy.
Budweiser and Gerber Among Larger U.S. Brands Overseas
Some of the most well-known American brands aren't actually so American, after all.
What to Watch Monday, May 5: Earnings From Drug Giant Pfizer
Investors will be tracking Pfizer's earnings when they report first-quarter results on May 5. Expectations are for earnings of $0.55 a share on sales of $12.07 billion.
Day Ahead: Awash in Earnings
Futures point higher; blockbuster drug deal boosts European markets.
Day Ahead: Quarter Final
Update: Futures positive as quarter closes; J&J sells ortho unit.
Array CEO: Partnerships Smart While Cancer Drug Develops
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
Rules of the Game: In International Waters
When investing beyond your own shores, choose value over growth.
Looking Across the Pond
Some European names look ripe for investment right now.
Early-Morning Market Look
Let's take a peek at overnight and early-morning price action in the major asset classes. Exit light Enter night Take my hand We're off to never never land. -- Metallica, "Enter Sandman" Let's take a peek at overnight and early-morning price action ...
Takeover Bait for Profitable 2013 Fishing
Two domestic exploration and production names that scream 'buy me' are Devon and Southwestern.
A Prescription for Election Fever
Now is the time to pop the pharmaceutical pill and buy.
UBS Posts Worse-than-Expected Q2 Profit: Hot Trends
A look at the day's most searched trends on the Web, including UBS after the Swiss bank posted a worse-than-expected second-quarter profit due to losses it incurred from the Facebook initial public offering.
Two Stocks Near 9-Month Consolidation
IRM has been trading in a declining triangle pattern since July. Technical indications of NVS are also positive.
Amgen Founding CEO George B. Rathmann Dies: Hot Trends
A look at the day's most searched trends on the Web, including Amgen after the passing of its founding CEO.
The Anatomy of a Head-and-Shoulders Bottom
Plenty of stocks are exhibiting these formations -- here's how to tell where they'll go from here.
The Day Ahead: Selling Pressure Mounts
Indicators pointed to a not-so-super Tuesday, as international growth concerns weighed on U.S futures.
